A Literature Review of Quetiapine for Generalized Anxiety Disorder

@article{Kreys2015ALR,
  title={A Literature Review of Quetiapine for Generalized Anxiety Disorder},
  author={Tiffany-Jade Kreys and Stephanie V Phan},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2015},
  volume={35}
}
To evaluate the efficacy and tolerability of quetiapine for the treatment of generalized anxiety disorder (GAD), a literature search of the Medline database was conducted from inception to May 2014. The search was not restricted by language. Keywords used in the search were quetiapine and generalized anxiety disorder or anxiety. All studies assessing the use of quetiapine as monotherapy or adjunct therapy for the primary management of GAD in adults 18–65 years of age were included in this… 
Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review
TLDR
An algorithmic approach to the pediatric and adult patient with GAD is described and considerations for the use of selected medications in these patients are highlighted.
Pharmacological Management of Anxiety Disorders in the Elderly
TLDR
Although tricyclic/tetracyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) may be effective in the elderly, their side effect and safety profiles are suboptimal and thus are not recommended in late-life.
New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments
TLDR
This review intends to provide a comprehensive summary of the most recent research done in the field of anxiety disorders in the elderly, recent findings in clinical research, neuroimaging, neuroendocrinology, and neuropsychology are covered.
CLINICAL PRACTICE. Generalized Anxiety Disorder.
TLDR
First-line treatments for generalized anxiety disorder are cognitive behavioral therapy, pharmacotherapy with a selective serotonin-reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitors (SNRI), or cognitive Behavioral therapy in conjunction with either an SSRI or an SNRI.
A study of the action of risperidone at 5-HT2A receptors
A STUDY OF THE ACTION OF RISPERIDONE AT 5-HT2A RECEPTORS By Supriya A. Gaitonde, Ph.D. A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at
Anxiety Disorders in the Elderly.
TLDR
Although SSRIs have proven more effective than psychotherapy in late-life anxiety, many elderly anxious subjects prefer psychotherapeutic interventions, and these interventions appear to work best when tailored for the needs, expectations, and cultural background of older anxious subjects.
Prescribing according to diagnosis: how psychiatry is different
  • David Taylor
  • Medicine
    World psychiatry : official journal of the World Psychiatric Association
  • 2016
TLDR
The licensed uses of a medicine are thus merely those for which formal approval has been sought and obtained by the manufacturer and other beneficial uses are certainly not precluded by a drug's label.
Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications
TLDR
The first step of the development of a web application that is able to make polypharmacy, high dose usage and off label usage of antipsychotics visible to clinicians is described.
Effect of a dosing-time on quetiapine-induced acute hyperglycemia in mice.
Quetiapine modified‐release versus immediate‐release in early psychosis
TLDR
There are clear differences between quetiapine immediaterelease (IR) and modified‐release (MR) that may have clinical significance in this patient group.
...
1
2
...

References

SHOWING 1-10 OF 41 REFERENCES
Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study
TLDR
Low-dose augmentative quetiapine may be an useful treatment option for patients with GAD and partial/no response to SSRIs and limited sample size may limit the confidence in the reported results.
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings
TLDR
The data do not support the addition of quetiapine to continued paroxetine CR for individuals with GAD who remain symptomatic after 10 weeks of prospective antidepressant pharmacotherapy and suggest that further research examining strategies for GAD refractory to antidepressants is needed.
The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study.
  • A. Gabriel
  • Psychology, Medicine
    La Clinica terapeutica
  • 2011
TLDR
Quetiapine XR may have anxiolytic properties and could be used effectively as adjunctive treatment with SSRIs in GAD patients with partial response to SSRs or SNRISs, however double blind randomized trials are needed to support these results.
New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
  • B. Baune
  • Psychology, Medicine
    Neuropsychiatric disease and treatment
  • 2008
TLDR
The available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD and some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients.
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.
TLDR
In patients with GAD and an inadequate response to SSRI/SNRIs, adjunctive quetiapine XR did not show a statistically significant effect for the primary endpoint at week 8, although some secondary endpoints were statistically significant vs placebo.
Anxiety disorders: a comprehensive review of pharmacotherapies.
TLDR
There is evidence from multiple randomized, placebo-controlled trials and meta-analyses of pharmacological treatments of anxiety disorders to support the use of selective serotonin reuptake inhibitors as first-line pharmacotherapy in these disorders, and a number of them have received US Food and Drug Administration approval for these indications.
Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials
TLDR
Analysis of metabolic tolerability data suggests that even low doses of quetiapine may lead to increase in weight and triglycerides across psychiatric disorders, Interestingly, however, quetuapine-induced elevations in low-density lipoprotein and total cholesterol seem to be restricted to schizophrenia patients.
Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
TLDR
Patients with schizophrenia or mania had a higher tolerability and a lower sensitivity than those with bipolar depression, MDD, or GAD, and patients with GAD had the poorest tolerability during treatment with quetiapine-XR.
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial
TLDR
Quetiapine XR monotherapy reduced the risk of anxiety symptom recurrence in patients with GAD stabilized on quetiapo fumarate, with tolerability results consistent with the known profile of quetuapine.
...
1
2
3
4
5
...